In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
After finishing at $132.72 in the prior trading day, Inspire Medical Systems Inc (NYSE: INSP) closed at $128.61, down -3.10%. In other words, the price has decreased by -$3.10 from its previous closing price. On the day, 0.77 million shares were traded.
Ratios:
Our goal is to gain a better understanding of INSP by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 10.27 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 48.11. For the most recent quarter (mrq), Quick Ratio is recorded 7.44 and its Current Ratio is at 9.01. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.05.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, BofA Securities on November 20, 2024, Upgraded its rating to Buy and sets its target price to $255 from $220 previously.
On May 08, 2024, BofA Securities Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $265 to $225.
On April 19, 2024, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $285.RBC Capital Mkts initiated its Outperform rating on April 19, 2024, with a $285 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 19 ’25 when Rondoni John sold 1,734 shares for $149.38 per share. The transaction valued at 259,025 led to the insider holds 13,766 shares of the business.
JOHN RONDONI bought 1,734 shares of INSP for $259,025 on May 19 ’25. On May 02 ’25, another insider, mcCormick Shawn, who serves as the Director of the company, sold 360 shares for $160.00 each. As a result, the insider received 57,600 and left with 24,046 shares of the company.
Valuation Measures:
As of this moment, Inspire’s Price-to-Earnings (P/E) ratio for their current fiscal year is 59.27, and their Forward P/E ratio for the next fiscal year is 39.75. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.67. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.52 while its Price-to-Book (P/B) ratio in mrq is 5.96.
Stock Price History:
Over the past 52 weeks, INSP has reached a high of $225.00, while it has fallen to a 52-week low of $123.00. The 50-Day Moving Average of the stock is -13.12%, while the 200-Day Moving Average is calculated to be -28.29%.
Shares Statistics:
A total of 29.47M shares are outstanding, with a floating share count of 27.62M. Insiders hold about 6.36% of the company’s shares, while institutions hold 111.39% stake in the company.
Earnings Estimates
Its stock is currently analyzed by 14.0 different market analysts. The consensus estimate for the next quarter is $0.6, with high estimates of $0.72 and low estimates of $0.43.
Analysts are recommending an EPS of between $2.3 and $2.2 for the fiscal current year, implying an average EPS of $2.26. EPS for the following year is $3.21, with 14.0 analysts recommending between $3.69 and $2.82.
Revenue Estimates
16 analysts predict $214.5M in revenue for the current quarter. It ranges from a high estimate of $217.6M to a low estimate of $211.23M. As of the current estimate, Inspire Medical Systems Inc’s year-ago sales were $195.88MFor the next quarter, 16 analysts are estimating revenue of $240.34M. There is a high estimate of $244.06M for the next quarter, whereas the lowest estimate is $233.9M.
A total of 18 analysts have provided revenue estimates for INSP’s current fiscal year. The highest revenue estimate was $954.49M, while the lowest revenue estimate was $940M, resulting in an average revenue estimate of $949.19M. In the same quarter a year ago, actual revenue was $802.8MBased on 18 analysts’ estimates, the company’s revenue will be $1.11B in the next fiscal year. The high estimate is $1.13B and the low estimate is $1.09B.
